{"filing":{"accession_number":"0001193125-26-268477","cik":"0001776111","ticker":"MBX","company_name":"MBX Biosciences, Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"mbx-20260612.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526268477/mbx-20260612.htm"},"events":[{"id":10391,"run_id":9113,"accession_number":"0001193125-26-268477","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"MBX Biosciences announced positive one-year clinical trial data for canvuparatide, its lead therapeutic candidate for chronic hypoparathyroidism, demonstrating a 57% responder rate, favorable pharmacokinetics supporting once-weekly dosing, evidence of physiologic PTH replacement, and a generally well-tolerated safety profile with no new safety signals.","company_name":"MBX Biosciences, Inc.","ticker":"MBX","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":6696,"accession_number":"0001193125-26-268477","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"MBX Biosciences disclosed one-year clinical trial data for canvuparatide, a potential PTH replacement therapy in chronic hypoparathyroidism, via press release and investor conference call. While this is clinical trial progress rather than a traditional earnings release, the disclosure of positive Phase 2 trial data for a lead therapeutic candidate would materially affect investor assessment of the company's pipeline and development prospects. This does not fit neatly into earnings_release (which typically refers to financial results) but is clearly material to a biopharmaceutical company's valuation and investor decision-making.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:18:44.649444+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6697,"accession_number":"0001193125-26-268477","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"MBX Biosciences announced positive one-year clinical trial data for canvuparatide in chronic hypoparathyroidism, showing a 57% responder rate at one year, favorable pharmacokinetics supporting once-weekly dosing, evidence of physiologic PTH replacement, and a generally well-tolerated safety profile with no new safety signals. While this is a clinical trial update rather than a traditional earnings release, M\u0026A activity, or other specifically enumerated event type, the positive efficacy and safety data for a lead product candidate in a Phase 2 trial would materially affect a reasonable investor's assessment of the company's prospects and pipeline value.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:18:44.649444+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6696,"accession_number":"0001193125-26-268477","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"MBX Biosciences disclosed one-year clinical trial data for canvuparatide, a potential PTH replacement therapy in chronic hypoparathyroidism, via press release and investor conference call. While this is clinical trial progress rather than a traditional earnings release, the disclosure of positive Phase 2 trial data for a lead therapeutic candidate would materially affect investor assessment of the company's pipeline and development prospects. This does not fit neatly into earnings_release (which typically refers to financial results) but is clearly material to a biopharmaceutical company's valuation and investor decision-making.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:18:44.649444+00:00","company_name":"MBX Biosciences, Inc.","ticker":"MBX","filing_date":"2026-06-12"},{"id":6697,"accession_number":"0001193125-26-268477","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"MBX Biosciences announced positive one-year clinical trial data for canvuparatide in chronic hypoparathyroidism, showing a 57% responder rate at one year, favorable pharmacokinetics supporting once-weekly dosing, evidence of physiologic PTH replacement, and a generally well-tolerated safety profile with no new safety signals. While this is a clinical trial update rather than a traditional earnings release, M\u0026A activity, or other specifically enumerated event type, the positive efficacy and safety data for a lead product candidate in a Phase 2 trial would materially affect a reasonable investor's assessment of the company's prospects and pipeline value.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:18:44.649444+00:00","company_name":"MBX Biosciences, Inc.","ticker":"MBX","filing_date":"2026-06-12"}]}